Paul Mayor, MD, Gynecologic Oncology Fellow, Roswell Park Cancer Institute, discusses neuroendocrine carcinoma in gynecologic tumors.

In a comprehensive genomic analysis of neuroendocrine carcinoma of gynecologic and breast tumors, investigators identified mutations in various pathways. Mayor said that there were a significant number of 

 and Rb mutations, which are very common in neuroendocrine tumors from sites other than the gynecologic tract. This was expected.

There were a significant number of actionable mutations in the gynecologic subgroup, which Mayor said was unexpected. These actionable mutations were found in the mTOR, MEK, and homologous recombination repair pathways. About 60% of the patients had a mutation that was actionable. A large number of 

 mutations were found in cervix and uterine primaries, Mayor added. These tumors can be targeted with agents that are currently on the market.

Videos

Paul Mayor, MD, Gynecologic Oncology Fellow, Roswell Park Cancer Institute, discusses neuroendocrine carcinoma in gynecologic tumors.
 

Paul Mayor, MD

Articles

Dr. Mayor on Neuroendocrine Carcinoma in Gynecologic Tumors